When was Ocumension Therapeutics stock made available for the first time to the public?

The IPO Date for Ocumension Therapeutics is 2020-07-10. On this 2020-07-10, Ocumension Therapeutics stock was made publicly available.

Where is the headquarters of Ocumension Therapeutics stock?

Headquarters information for Ocumension Therapeutics is currently unavailable. We'll update this as soon as it's available.

What industry does Ocumension Therapeutics belong to?

The Ocumension Therapeutics belongs to Biotechnology.

Ocumension Therapeutics

1477.HK•HKSE

Healthcare

Biotechnology

HK$9.47

HK$-0.97(-9.29%)

Ocumension Therapeutics (1477.HK) Company Profile & Overview

Explore Ocumension Therapeutics’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Ocumension Therapeutics (1477.HK) Company Profile & Overview

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.

SectorHealthcare

IndustryBiotechnology

CEOYe Liu

Contact Information

https://www.ocumension.com

No. 1858 Yinzhongnan Road, Suzhou

Company Facts

489 Employees

IPO DateJul 10, 2020

CountryCN

Actively Trading

Frequently Asked Questions

;